Answers are grounded in this paper and cite their sources.
OBJECTIVE: To develop and experimentally validate an explainable artificial intelligence (AI) framework that extracts formulation rules for niosomal drug delivery systems from published data and delivers them through a decision-support platform. SIGNIFICANCE: Niosome performance depends on many interacting formulation and process variables, and optimization still relies largely on trial-and-error experimentation. Converting existing formulation knowledge into interpretable, experimentally verified rules could make early-stage development faster and less resource-intensive. METHODS: A database of 33 optimized niosomal formulations (approximately 30 drugs, BCS classes I-V) was compiled from peer-reviewed studies. Correlation analysis, XGBoost feature importance, and SHAP were used to relate formulation variables to particle size, entrapment efficiency (EE%), drug release, and release time. The extracted trends were tested experimentally using 17 diclofenac sodium-loaded niosomal formulations prepared by thin-film hydration. The dataset was expanded to 1000 samples using SMOTE to train XGBoost predictive models, which were evaluated on the original formulations and integrated with a Qwen-based large language model. RESULTS: values of 0.97-0.99 on the original formulations, and the resulting Niosome AI Expert platform showed general agreement between predicted and reported outcomes. CONCLUSIONS: Combining machine learning, explainable AI, and experimental verification can convert existing formulation knowledge into a practical decision-support tool that reduces reliance on trial-and-error niosome development.
No takes yet. Share an insight, caveat, or question.
Salem et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: